ImageneBio, Inc. Financing Cash Flow
ImageneBio, Inc. (IMA) reported Financing Cash Flow of $24.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- ImageneBio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $28.05M, a 115.47% increase year-over-year.
- ImageneBio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$3.24M, a 12114.81% decline year-over-year.
- ImageneBio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ImageneBio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $122.42M.
- ImageneBio, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $135.47M, a 1861.60% increase from fiscal 2024.
- ImageneBio, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $6.91M, a 90.91% decline from fiscal 2023.
- ImageneBio, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $75.98M, a 6838.81% increase from fiscal 2022.
- ImageneBio, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.09M, a 99.17% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $24.80M 10-Q · filed 2026-08-05 | $24.80M derived: sum of 3 quarters · filed 2026-08-05 | $147.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.24M 10-Q · filed 2026-05-07 | -$3.24M derived: sum of 2 quarters · filed 2026-05-07 | $119.18M derived: sum of 3 quarters · filed 2026-05-07 | $132.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $122.42M derived: sum of 2 quarters · filed 2026-03-10 | $135.44M derived: sum of 3 quarters · filed 2026-08-05 | $135.47M 10-K · filed 2026-03-10 |
| 2025-09-30 | $122.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $135.44M derived: sum of 2 quarters · filed 2026-08-05 | $135.47M 10-Q · filed 2025-11-12 | $142.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $13.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $13.04M 10-Q · filed 2026-08-05 | $19.95M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-03-31 | $27.00K 10-Q · filed 2026-05-07 | $6.93M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $6.91M 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $38.98M derived: sum of 2 quarters · filed 2025-03-06 | $75.98M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $38.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $75.92M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $37.00M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $25.00K derived: sum of 2 quarters · filed 2024-03-12 | $600.00K derived: sum of 3 quarters · filed 2024-03-12 | $1.09M 10-K · filed 2024-03-12 |
| 2022-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $599.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.09M 10-Q · filed 2023-11-09 | $1.33M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $575.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.07M 10-Q · filed 2023-08-10 | $1.31M derived: sum of 3 quarters · filed 2023-08-10 | $1.38M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $495.00K 10-Q · filed 2023-05-15 | $731.00K derived: sum of 2 quarters · filed 2023-05-15 | $800.00K derived: sum of 3 quarters · filed 2023-05-15 | -$295.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $305.00K derived: sum of 2 quarters · filed 2023-03-14 | -$790.00K derived: sum of 3 quarters · filed 2023-03-14 | $131.74M 10-K · filed 2023-03-14 |
| 2021-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$1.03M derived: sum of 2 quarters · filed 2022-11-07 | $131.50M 10-Q · filed 2022-11-07 | $247.66M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $131.43M 10-Q · filed 2022-08-11 | $247.60M derived: sum of 3 quarters · filed 2022-08-11 | $247.60M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $132.53M 10-Q · filed 2022-05-12 | $248.69M derived: sum of 2 quarters · filed 2022-05-12 | $248.69M derived: sum of 3 quarters · filed 2022-05-12 | $248.69M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $116.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $116.16M derived: sum of 2 quarters · filed 2022-03-17 | $116.16M derived: sum of 3 quarters · filed 2022-03-17 | $116.18M 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $21.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $21.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $21.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |